Candriam S.C.A. Arbutus Biopharma Corp Transaction History

Candriam S.C.A.

2 transactions

Quarter	Operation	Price Per share	shares change	shares Held	SEC Form
Q2 2019 Aug 01, 2019	SELL	$1.46 - $4.44 $153,300 - $466,200	-105,000 Closed	0 $0
Q3 2018 Nov 07, 2018	BUY	$7.85 - $12.35 $824,250 - $1.3 Million	105,000 New	105,000 $992,000

156

99.5M

2.31M

525K

Ticker ABUS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 149,951,008
Market Cap $544M
Description
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously delivered RNA interference product candidate, which in Phase Ia/Ib clinical tria...

Get notified when there are updates to the investment portfolio of Candriam S.C.A., based on Form 13F filings with the SEC.

Stay updated on Candriam S.C.A. with notifications on news.